Obesity

Biotech Allison DeAngelis

STAT Plus: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

Don't Miss STAT Staff

STAT stories you might have missed in 2023

The Obesity Revolution Elaine Chen, Andrew Joseph, and Damian Garde

STAT Plus: What comes after Wegovy? The quest to eradicate obesity

Pharmalot Ed Silverman

STAT Plus: 3 issues to watch in pharma in 2024

The Obesity Revolution Andrew Joseph

STAT Plus: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them

Health Isabella Cueto and Elaine Chen

Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch in 2024

Biotech Damian Garde

STAT Plus: 3 trends to watch in biotech in 2024

Health Elaine Chen

STAT Plus: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility

Biotech Adam Feuerstein

STAT Plus: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study

The Readout Damian Garde

STAT Plus: Is it time to worry about Moderna?

First Opinion George Hampton

Europe’s lessons for the U.S. on how to cover weight loss drugs

Biotech Jason Mast

STAT Plus: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts

Pharma Andrew Joseph

STAT Plus: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion

Pharma Andrew Joseph and Elaine Chen

STAT Plus: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial

The Obesity Revolution Allison DeAngelis and Elaine Chen

STAT Plus: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle

Health Andrew Joseph

Type 2 diabetes prevention programs can work at large scale, study finds

Insurance Brittany Trang and Elaine Chen

AMA urges coverage of obesity treatments as payers balk at costs

Biotech Matthew Herper

STAT Plus: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug

Pharma Elaine Chen

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

Pharma Elaine Chen

STAT Plus: Wegovy cuts risk of heart attacks in milestone cardiovascular trial

Pharma Andrew Joseph

STAT Plus: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion

Pharma Elaine Chen and Damian Garde

STAT Plus: Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound

The Readout Damian Garde

STAT Plus: Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Biotech Robert Weisman — Boston Globe

STAT Plus: Massachusetts biotechs seek to piggyback on weight loss drug boom

Pharmalot Ed Silverman

STAT Plus: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro

Pharma Elaine Chen

STAT Plus: Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award

Health Elaine Chen

STAT Plus: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues